MARKET

REGN

REGN

Regeneron Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

620.21
-1.00
-0.16%
After Hours: 620.03 -0.18 -0.03% 19:54 08/07 EDT
OPEN
621.00
PREV CLOSE
621.21
HIGH
627.46
LOW
614.55
VOLUME
432.74K
TURNOVER
--
52 WEEK HIGH
664.64
52 WEEK LOW
271.37
MARKET CAP
63.50B
P/E (TTM)
31.16
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 27 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average REGN stock price target is 669.68 with a high estimate of 800.00 and a low estimate of 550.00.

EPS

REGN News

More
Trump signs executive action to boost U.S. production of 'essential' drugs
"We will bring our pharmaceutical and medical supply chains home - we're going to bring them home where they belong - and we will end reliance on China," P
seekingalpha · 23h ago
Regeneron Pharmaceuticals, Inc. -- Moody's rates Regeneron's sr. notes Baa3; stable outlook
Moody's Investors Service ("Moody's") assigned a Baa3 rating to the new senior unsecured notes of Regeneron Pharmaceuticals, Inc. ("Regeneron"). "Regeneron's investment grade rating reflects growing global scale, strong scientific expertise, and an extremely
Moody's · 1d ago
Jim Cramer: No Shinola! Sellers Are Wrong on These 3 Stocks
People got a kick out of what I said at the top of "Mad Money" on Tuesday night, that the buyers and sellers are sometimes so stupid that they make moves that a bag of hammers would know better to pass on. Remember, Livongo helps people with chronic condition
TheStreet.com · 2d ago
US STOCKS-Wall St gains on Disney's surprise profit, fiscal aid hopes
Reuters · 2d ago
Regeneron Pharma gains on strong Q2 and earnings beat
Regeneron Pharmaceuticals (REGN) Q2 results: Revenues: $1,952M (+23.7%); Eylea sales in U.S.: $1,113.7M (-4.0%); Dupixent global net sales: $945M (+70%); L
seekingalpha · 2d ago
US STOCKS-Wall St rises on Disney's surprise profit, services sector data
Reuters · 2d ago
Regeneron Pharmaceuticals, Inc. -- Moody's assigns Baa3 issuer rating to Regeneron
Moody's Investors Service ("Moody's") assigned a Baa3 issuer rating to Regeneron Pharmaceuticals, Inc. ("Regeneron"). "Regeneron's investment grade rating reflects growing global scale, strong scientific expertise, and an extremely conservative balance sheet,
Moody's · 2d ago
Regeneron Pharmaceuticals EPS beats by $1.20, beats on revenue
Regeneron Pharmaceuticals (NASDAQ:REGN): Q2 Non-GAAP EPS of $7.16 beats by $1.20; GAAP EPS of $7.61 beats by $2.54. Revenue of $1.95B (+23.4% Y/Y) beats by
seekingalpha · 2d ago

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About REGN

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
More

Webull offers kinds of Regeneron Pharmaceuticals Inc stock information, including NASDAQ:REGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading REGN stock methods without spending real money on the virtual paper trading platform.